Drug transporter pharmacogenetics in nucleoside-based therapies

2010 ◽  
Vol 11 (6) ◽  
pp. 809-841 ◽  
Author(s):  
Ekaitz Errasti-Murugarren ◽  
Marçal Pastor-Anglada
Keyword(s):  
Drug Transporter

A genome-wide association study of nausea incidence in varenicline-treated cigarette smokers

2021 ◽  
Author(s):  
Meghan J Chenoweth ◽  
Caryn Lerman ◽  
Jo Knight ◽  
Rachel F Tyndale
Keyword(s):  
Association Study ◽  
Side Effect ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Common Side Effect ◽  
Drug Transporter ◽  
Transporter Gene ◽  
Cigarette Smokers ◽  
Genome Wide ◽  
A Genome

Abstract Introduction Varenicline is the most efficacious smoking cessation treatment, however long-term cessation rates tend to be <25%. Nausea, the most common side effect of varenicline, observed in ~28% of individuals treated, peaks early following treatment initiation and reduces cessation success. Genetic variation influences treatment response, however genetic contributors to individual differences in side effects are less understood. Methods We conducted a genome-wide association study of nausea incidence at one week following the initiation of varenicline treatment (corresponding to the target quit date) in 189 cigarette smokers of European ancestry (NCT01314001). Additive genetic models examining the likelihood of experiencing any versus no nausea controlled for population substructure, age, and sex. Variants with minor allele frequencies (MAF) ≥ 10% were considered. Results Fifty-seven (30.2%) out of 189 participants reported nausea. The top variant associated with nausea was rs1568209 (OR=2.61 for A vs. G allele; 95% CI=1.65,4.15; P=2.1e-7; MAF=48.7%), mapping to the SLCO3A1 drug transporter gene on chromosome 15. In the same trial, rs1568209 was not associated with nausea in either the nicotine patch (P=0.56; n=181) or placebo (P=0.59; n=174) arms. In varenicline-treated smokers, the incidence of nausea was higher in females (44.6%; n=74) versus males (20.9%; n=115) (P=0.001), however there was no evidence of a difference in the influence of rs1568209 on nausea between the sexes (P for sex*genotype interaction=0.36). Future studies in larger samples are required to test the robustness of this finding. Conclusions Variation in SLCO3A1 may influence the risk for developing nausea in varenicline-treated smokers, which may alter adherence and cessation. Implications Varenicline-associated nausea reduces adherence and limits cessation success. Previous candidate gene association studies showed genetic factors influence nausea on varenicline. This pilot genome-wide investigation of nausea, the most common side effect associated with varenicline treatment and an importance cause of treatment discontinuation, suggests the potential involvement of common variation in the SLCO3A1 drug transporter gene.

scholarly journals Chitosan-covered liposomes as a promising drug transporter: nanoscale investigations

RSC Advances ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 1503-1516
Author(s):  
Lemaalem Mohammed ◽  
Hadrioui Nourddine ◽  
El Fassi Saad ◽  
Derouiche Abdelali ◽  
Ridouane Hamid
Keyword(s):  
Membrane Structure ◽  
Molar Fraction ◽  
Drug Transporter ◽  
Liposome Membrane ◽  
Structure And Dynamics

In this paper, we studied the graft chitosan conformation and its influence on the liposome membrane structure and dynamics as a function of the grafting molar-fraction.

scholarly journals Drug Transporter Expression and Localization in Rat Nasal Respiratory and Olfactory Mucosa and Olfactory Bulb: Fig. 1.

2010 ◽  
Vol 38 (10) ◽  
pp. 1644-1647 ◽  
Author(s):  
Mary Beth Genter ◽  
Mansi Krishan ◽  
Lisa M. Augustine ◽  
Nathan J. Cherrington
Keyword(s):  
Olfactory Bulb ◽  
Olfactory Mucosa ◽  
Drug Transporter ◽  
Transporter Expression

scholarly journals Xanthines Down-Regulate the Drug Transporter ABCG2 and Reverse Multidrug Resistance

2011 ◽  
Vol 81 (3) ◽  
pp. 328-337 ◽  
Author(s):  
Rui Ding ◽  
Jia Shi ◽  
Kirk Pabon ◽  
Kathleen W. Scotto
Keyword(s):  
Multidrug Resistance ◽  
Drug Transporter

Development of an LC–MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions

2018 ◽  
Vol 1073 ◽  
pp. 80-89 ◽  
Author(s):  
Emmanuel Njumbe Ediage ◽  
Lieve Dillen ◽  
Ann Vroman ◽  
Luc Diels ◽  
Annett Kunze ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Drug Transporter ◽  
Coproporphyrin I
Sign in / Sign up

Export Citation Format

Share Document